RT Journal Article
SR Electronic
T1 Respiratory infection during lithium and valproate medication: a within-individual prospective study of 50,000 patients with bipolar disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.04.20090084
DO 10.1101/2020.05.04.20090084
A1 Landén, Mikael
A1 Lichtenstein, Paul
A1 Larsson, Henrik
A1 Song, Jie
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090084.abstract
AB Objective In vitro studies have demonstrated that lithium has antiviral properties, but evidence from human studies is scarce. Lithium is used as a mood stabilizer to treat patients with bipolar disorder. Here, the aim was to investigate the association between lithium use and the risk of respiratory infections in patients with bipolar disorder. To rule out the possibility that a potential association could be due to lithium’s effect on psychiatric symptoms, we also studied the effect of the most common alternative to lithium to prevent mood episodes in bipolar disorder, valproate.Method We followed 51,509 individuals diagnosed with bipolar disorder in the Swedish Patient register 2005–2013. We applied a with-individual design using stratified Cox regression to estimate the hazard ratios (HRs) of respiratory infections during treated periods compared with untreated periods.Results During follow-up, 5,760 respiratory infections were documented in the Swedish Patient Register. The incidence rate was 28% lower during lithium treatment (HR 0.73, 95% CI 0.61–0.86) and 35% higher during valproate treatment (HR 1.35, 95% CI 1.06–1.73) compared with periods off treatment.Conclusions This study provides real-world evidence that lithium protects against respiratory infections and suggests that the repurposing potential of lithium for antiviral effects is worthy of investigation.Competing Interest StatementM.L. declares that, over the past 36 months, he has received lecture honoraria from Lundbeck pharmaceutical. H.L. declares that he has served as a speaker for Evolan Pharma and Shire/Takeda and has received research grants from Shire/Takeda; all outside the submitted work.Funding StatementThe study was supported in part by the Swedish Medical Research Council (ML: 2018-02653). The sponsor had no role in the interpretations of results or drafting the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors had full and ongoing access to the original data presented and analysed in this study. Due to Swedish legal restrictions, register data cannot be shared.